| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Cocrystal Pharma Inc. | CC-42344 | Influenza A | Phase 2a | Ongoing | Oral | Antiviral |
| Cocrystal Pharma Inc. | CC-42344 | Influenza A | Phase 2a | Ongoing | Oral | Antiviral |
| Cocrystal Pharma Inc. | CC-31244 | Hepatitis C | Phase 2a | Looking for Funding | Oral | Antiviral |
| Cogent Biosciences Inc. | Bezuclastinib and SUTENT (sunitinib) - (PEAK) | Gastrointestinal Stromal Tumors (GIST) | NDA Filing | Trial Planned | Oral | Oncology |
| Cogent Biosciences Inc. | Bezuclastinib - (SUMMIT) | Non-Advanced Systemic Mastocytosis | NDA Filing | Data Released | oral | Immunology |
| Cogent Biosciences Inc. | Bezuclastinib - (APEX) | Advanced Systemic Mastocytosis | Phase 2 | Data Released | Oral | Oncology |
| Cognition Therapeutics Inc. | Zervimesine (CT1812) - (SHINE) | Mild-to-Moderate Alzheimer's Disease | Phase 3 | Trial Planned | Oral | Neurology |
| Cognition Therapeutics Inc. | CT1812 - (SEQUEL) | Mild-to-Moderate Alzheimer's Disease | Phase 2 | Trial Completed | Oral | Neurology |